Entropy Neurodynamics (ASX:ENP) said the results from its phase 2a clinical trial of its TRP-8802 drug candidate, or oral psilocin, for the treatment of binge eating disorder showed a sustained reduction in binge-eating episodes of 80% across patients, according to a Tuesday Australian bourse filing.

The results were maintained through the 14-week follow-up period, alongside improvements across secondary outcomes, including reductions in anxiety, depression, psychological inflexibility, and waist circumference. They were published in the peer-reviewed Journal of Eating Disorders.

The study enrolled six patients and involved therapy sessions before a single dose of TRP-8802, followed by structured supportive therapy. Of the six patients enrolled, five were available for data evaluation. Four of five participants were classified as none-to-mild binge eating disorder by week 14, per the filing.

Its shares jumped 3% in recent trading on Tuesday.